Redefine what’s possible with Grace’s customized
pharmaceutical and nutraceutical solutions

Grace’s focus on innovation and advanced technical expertise is built on a 100-year history of exceeding customer expectations throughout the drug developmentprocess, from discovery to commercialization.

Learn more >

  • Expertly synthesized fine chemicals with three fully integrated North American sites#
  • Highly efficient DAVISIL®, VYDAC® and VYKING™ chromatography resins 
  • Unique SYLOID® multi-functional excipients
  • Exceptionally innovative SILSOL® silica active ingredient delivery technology

GRACE®, DAVISIL®, VYDAC®, VYKING™, SYLOID® and SILSOL® are trademarks, registered in the United States and/or other countries, of W. R. Grace & Co.-Conn.TECHNOLOGY | TALENT | TRUST™ is a trademark of W. R. Grace & Co.-Conn. This trademark listing has been compiled using available published information asof the publication date and may not accurately reflect current trademark ownership or status. © Copyright 2022 W. R. Grace & Co.-Conn. All rights reserved

Go to article: Home | Continuous manufacturing cautiously builds on hypeGo to article: In this issueGo to article: CSafe GlobalGo to article: ContentsGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: SHL Medical Company Insight Go to article: SHL MedicalGo to article: WR GraceGo to article: CommentGo to article: CMO agreements need to go public, but ‘glib’ onshoring not the answerGo to article: Biologic sales forecast to pass innovative small molecule sales in next five yeaGo to article: The telemedicine community has rallied to provide support to patients in UkraineGo to article: Osteoarthritis pipeline shifting from analgesics to disease-modifying treatmentsGo to article: BioLife SolutionsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: In DepthGo to article: Continuous manufacturing builds on hype but adoption remains gradual Go to article: Can Relmada’s fast-acting pill for major depressive disorder compete inGo to article: Access to CAR-T therapies in Central and Eastern Europe in “catch-up” mode compaGo to article: How ambitious are the emissions targets of pharma and biotech companies?Go to article: Should Covid-19 clinical trial plans still centre around EUAs?Go to article: BEA TechnologiesGo to article: Datwyler Company InsightGo to article: DatwylerGo to article: In DataGo to article: Top and emerging locations for M&A deals in the pharma industryGo to article: Deals relating to genomics increased in the pharma industry in H2 2021Go to article: Pharma industry companies are increasingly innovating in machine learningGo to article: BaxterGo to article: EventsGo to article: Next issue